Headquartered outside London in the UK but operating globally, our staff is distributed around the world. Our commercial team operates from the UK, U.S., Canada, and India. Our AI research groups are located in the UK and the UAE; and our software development teams are based in India (front-end) and Bangladesh (back-end). We are united in our dedication to developing a person-centric approach to healthcare that differs from the current population-based paradigm.
The team exploits its research experience carried out at top-ranked institutions at the forefront of AI and medicine, including Oxford, Cambridge, and the Karolinska Institute. OIA’s founders have published more than 200 papers in all the top-ranked journals in the areas of Artificial Intelligence, computational medicine, and systems immunology.
Our cross-disciplinary team consists of AI experts, medical leaders, and pioneers in IoT and engineering working at the forefront of science and technology. With our multidisciplinary approach, we are able to tackle some of the most pressing human health challenges, such as infection, cancer, antibiotic resistance, and tropical diseases from a technological and commercial-viability point of view.
We proudly embrace diversity, inclusion, and equality, which are among our core values.
Elected member of the London Mathematical Society and of the Canadian College of Health Leaders (CCHL), and Fellow of the Royal Society of Medicine.
Before joining the Machine Learning Group at the Department of Chemical Engineering and Biotechnology at the University of Cambridge, he was a Senior Researcher and faculty member in the Department of Computer Science, University of Oxford.
He has published over 100 papers and a dozen of books (Springer Nature, Cambridge University Press, WS/Imperial College), including A Computable Universe with a foreword by Sir Roger Penrose (Nobel Prize in Physics, 2020).
In 2021, he was appointed Senior Researcher by the Alan Turing Institute at the British Library in London to advise the UK and allies on the future of Artificial Intelligence for scientific discovery, a position funded by the U.S. Department of Defense. In this capacity, he has led discussions on the global stage, under the auspices of organisations such as the OECD.
After joining the Unit of Computational Medicine as an Assistant Professor he became the leader of the Algorithmic Dynamics Lab at the Karolinska Institute (the institution that awards the Nobel Prize in Physiology or Medicine), also affiliated with SciLifeLab and the Karolinska Hospital in Stockholm, Sweden.
He was a NASA Payload team member at MIT in Boston MA for the Mars Gravity Biosatellite to test the health effects of artificial microgravity on mammals. He helped develop the factual answering AI engine behind Siri and Alexa, reporting to Wolfram Research’s CEO, Stephen Wolfram in Champaign, IL.
He holds 2 PhDs, one in Comp Sci (Lille), and another in Epistemology (Paris, Sorbonne) and has more than 20 years experience in academia and industry in six countries.
He has been featured in Wired, the New York Times, Le Monde, Scientific American, New Scientist, The Independent, and the MIT Technology Review, among other media venues.
EMBA (SMU, Halifax, NS, Canada). As a Senior Healthcare Executive, Pam was formerly Director of Health Policy, Stakeholder Engagement and Chief Marketing Officer for Medtronic, Canada. Medtronic is the world’s largest medical devices company.
With more than 25 years in the healthcare industry, she began her career as a Critical Care Nurse and then moved to the pharmaceutical industry, successfully supporting women’s health, neurology and oncology faculties.
She is a visionary leader in the area of value-based healthcare strategies and is skilled in understanding how to position new solutions and technologies in today’s dynamic healthcare marketplace.
He has been a director of a number of public and private companies and is currently a director and the CEO of Range Energy Resources Inc., listed on the Canadian Securities Exchange.
His background includes hedge funds, corporate oil and gas, private equity and financial services, with experience and knowledge of capital markets from both the buy and sell perspectives.
He has spent time financing and advising a number of private and public entities, achieving notable success with Altus, Bluewave Energy, FCF Capital, Polaris Infrastructure.
A world authority in machine learning applied to systems medicine, single cell genomics, and causality.
He became a strategic chaired full professor in Computational Medicine, appointed a Director for the Computational Medicine Division, at the Dept. of Medicine, Karolinska Institute (the institution that awards the Nobel Prize in Medicine) & Division of Clinical Epidemiology, Karolinska Hospital. In 2014, he was named Faculty at the Science for Life Laboratory (SciLifeLab – National Center for Molecular Biosciences, Stockholm).
Since 2016, he is a Professor in Bioscience (BESE) and Professor in Computer Science (CEMSE) at KAUST. He is an ERC co-investigator (2013-) on causal discovery, ranked as outstanding (highest distinction among faculty, ERA 2012) at Karolinska, winner of the international DREAM competition (2008) on network inference.
Founder of two BioIT companies, in 2005 he became the winner of the national award for founding the most promising start-up company of the year.
He holds a Ph.D. in Medicine and MD (Karolinska), 2 years of posgraduate PhD courses in advanced mathematics (Royal Institute for Technology & Stockholm University), and 3 separate graduate degrees in Medicine (Karolinska), Philosophy, and Mathematics (Stockholm University).